<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02291770</url>
  </required_header>
  <id_info>
    <org_study_id>No.GRDEC 2014210H</org_study_id>
    <nct_id>NCT02291770</nct_id>
  </id_info>
  <brief_title>Treatment of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells</brief_title>
  <acronym>MSC-cGvHD</acronym>
  <official_title>Treatment of of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells. A Phase III Randomized Open Label Multi-center Study in Southern China.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou General Hospital of Guangzhou Military Command</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou First People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academy Military Medical Science, China</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Guangdong General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic Graft-versus-Host Disease (cGvHD) is a potentially lethal disorder. A variety of
      second line immunosuppressive agents have been investigated but no optimal treatment has
      emerged. There is therefore a need for novel treatment strategies. Mesenchymal stromal cells
      (MSC) exhibit immunomodulatory properties and a recent pilot study suggests a response rate
      of 70% in steroid- refractory patients. In the present randomized study the efficacy and
      safety of MSC treatment will be further studied in patients with cGvHD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients responding to treatment of cGvHD with MSC</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time without systemic immunosuppression</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidents of non-relapse mortality</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of life</measure>
    <time_frame>2 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Immune reconstitution including monitoring of absolute T-cell subsets, B-cells, NK-cells as well as biomarkers of cGvHD</measure>
    <time_frame>2 year</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Chronic Graft-Versus-Host Disease</condition>
  <arm_group>
    <arm_group_label>Mesenchymal stem cells (MSC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with newly diagnosed cGvHD receive primary treatment plus MSC:
MSC+prednisone+cyclosporine;
MSC+prednisone+tacrolimus;
MSC+prednisone+mycophenolate mofetil.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients with newly diagnosed cGvHD receive primary treatment:
Placebo+prednisone+cyclosporine;
Placebo+prednisone+tacrolimus;
Placebo+prednisone+mycophenolate mofetil.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mesenchymal Stromal Cells</intervention_name>
    <description>Mesenchymal stem cell(MSC). Patients with newly diagnosed cGvHD: prednisone 1mg/kg + cyclosporine or tacrolimus and MSC 2Ã—1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally).</description>
    <arm_group_label>Mesenchymal stem cells (MSC)</arm_group_label>
    <other_name>MSC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed cGvHD

          -  Informed consent obtained from patient and donor.

          -  Any patient who has undergone allogeneic stem cell transplantation with c GvHD.

          -  Have not received additional agent for cGVHD within 3 months.

          -  Expected life is more than 90 days.

          -  Adequate pulmonary function with no evidence of chronic obstructive or severe
             restrictive pulmonary disease.

          -  Adequate cardiac function with no evidence of uncontrolled high blood
             pressure,congestive heart failure, angina pectoris, acute myocardial infarction within
             6 months prior to the process.

        Exclusion Criteria:

          -  Invasive fungal disease.

          -  Active cytomegalovirus (CMV)/Epstein-Barr virus(EBV)/varicella disease).

          -  Patient is with a history of hypersensitivity to bovine products.

          -  Relapsed malignancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xin Du, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xin Du, Prof.</last_name>
    <phone>+86 02083827812-62122</phone>
    <email>miyadu@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jianyu Weng, Prof.</last_name>
    <phone>+86 02083827812-62122</phone>
    <email>wengjianyu1969@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xin Du</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Du, Prof.</last_name>
      <email>miaydu@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Peilong Lai, Dr.</last_name>
      <phone>+86 02083827812-62121</phone>
      <email>lai_peilong@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Weng J, He C, Lai P, Luo C, Guo R, Wu S, Geng S, Xiangpeng A, Liu X, Du X. Mesenchymal stromal cells treatment attenuates dry eye in patients with chronic graft-versus-host disease. Mol Ther. 2012 Dec;20(12):2347-54. doi: 10.1038/mt.2012.208. Epub 2012 Oct 16.</citation>
    <PMID>23070118</PMID>
  </reference>
  <reference>
    <citation>Weng JY, Du X, Geng SX, Peng YW, Wang Z, Lu ZS, Wu SJ, Luo CW, Guo R, Ling W, Deng CX, Liao PJ, Xiang AP. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant. 2010 Dec;45(12):1732-40. doi: 10.1038/bmt.2010.195. Epub 2010 Sep 6.</citation>
    <PMID>20818445</PMID>
  </reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2014</study_first_submitted>
  <study_first_submitted_qc>November 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2014</study_first_posted>
  <last_update_submitted>November 11, 2014</last_update_submitted>
  <last_update_submitted_qc>November 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Graft-Versus-Host Disease</keyword>
  <keyword>Mesenchymal Stromal Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

